| (Values in U.S. Thousands) | Feb, 2026 | Nov, 2025 | May, 2025 | Feb, 2025 | Nov, 2024 |
| Sales | 27,179 | 30,113 | 28,213 | 27,333 | 26,586 |
| Sales Growth | -9.74% | +6.73% | +3.22% | +2.81% | +6.05% |
| Net Income | 1,663 | 1,040 | 3,314 | 4,142 | 3,315 |
| Net Income Growth | +59.94% | -68.63% | -20.00% | +24.97% | +43.74% |
Cannara Biotech Inc (LOVE.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .
Fiscal Year End Date: 08/31